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Abstract
Background: To conduct an economic evaluation comparing ranolazine as add-on therapy to standard-of-care
(SoC) with SoC alone in patients with stable angina who did not respond adequately to first line therapy, in Greece.
Methods: A decision tree model was locally adapted in the Greek setting to evaluate the cost-utility of ranolazine
during a 6-month period. The analysis was conducted from a third-party payer perspective. The clinical inputs were
extracted from the published literature. The cost inputs considered in the model reflect drug acquisition, hospitalizations,
vascular interventions and monitoring of patients. The resource utilization data were obtained from 3 local experts. All
costs refer to the year 2014. Cost-effectiveness was assessed by means of the incremental cost per quality adjusted life
year (QALY) gained with the ranolazine as add-on therapy relative to SoC alone (ICER). Probabilistic sensitivity analysis
(PSA) was performed.
Results: Ranolazine as add-on therapy was more costly compared to SoC alone, as the 6-month total cost per patient
was €1170 and € 984, respectively. Patients received ranolazine plus SoC and SoC alone gained 0.3155 QALYs and 0.2752
QALYs, respectively. Ranolazine plus SoC resulted in an ICER equal to €4620 per QALY gained, well below the threshold of
€34,000 per QALY gained. The PSA showed that the likelihood of ranolazine plus SoC being cost-effective at the threshold
of €34,000 per QALY gained was 100 %.
Conclusions: Τhe results suggest that ranolazine as add–on treatment may be a cost-effective alternative for the
symptomatic treatment of patients with chronic stable angina in Greece.
Background
Chronic stable angina is one of the most common con-
ditions experienced by patients with heart disease with
significant detrimental effects on health related quality
of life, including pain, poor general health status, psy-
chological distress and restriction of activity [1, 2].
Moreover, there is evidence that patients with moderate
or severe angina have more than a twofold higher risk
for mortality compared to those with minimal or mild
angina [3]. Apart from mortality and morbidity, chronic
stable angina may impose great economic burden for
payers, health care systems [4], and patients as this con-
dition requires long-term pharmacological treatment, it
leads to frequent hospital admissions, requiring in many
cases expensive vascular interventions. Hospitalizations,
both with and without revascularization procedures are
the main cost drivers as they account for almost two
thirds of the total health care expenditures related to
chronic stable angina [4–6]. In addition to its direct
medical costs, chronic angina has been found to lead to
substantial productivity loss [7]. To be more precise,
studies have shown that the total cost (both direct and
indirect) of chronic angina is 2 to 3 times higher com-
pared to the direct one alone [7].
In this context, it is clear that the effective manage-
ment of chronic stable angina is important both for
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clinical and economic reasons. Effective treatment of
chronic stable angina should aim at reducing or ideally
abolishing symptoms, improve quality of life and prog-
nosis [2]. Lifestyle changes, pharmacological therapy and
revascularization procedures all have important roles in
the management of stable angina [8–10]. The pharmaco-
logical management of stable angina includes, nitrates,
b-blockers, calcium antagonists, statins, etc. [8–10].
Nonetheless, despite the aggressive use of conventional
antianginal therapies, many patients experience persistent
angina [11, 12]. For this reason, the need for additional
antianginal agents with novel mechanisms of action arose.
Several new drug have been tested for the management of
chronic stable angina [13–16]. Ranolazine (Ranexa®) is one
such antianginal agent [12]. Ranolazine is a drug that re-
duces angina symptoms, with a mechanism of action dif-
ferent from that of currently available pharmacological
therapies [17–20]. It was approved on July 9, 2008 by the
European Medicines Agency for use in patients with
chronic angina, who continue to be symptomatic on b-
blockers, and/or calcium antagonists [21].
The efficacy and safety of ranolazine as add-on
treatment for stable angina has been evaluated in
three clinical trials (MARISA [14], CARISA [17] and
ERICA [22]) and one large trial of patients with
non-ST elevation acute coronary syndrome (Merlin-
TIMI 36 [23]). These clinical trials showed an im-
provement in exercise performance and a decrease
in angina attacks.
Although, it is proven that ranolazine is an effective
treatment option for the management of chronic stable
angina, it may also impose a tangible cost to the health
care system and payers. Greece is going through a sig-
nificant economic crisis, which has resulted in major
budget constraints on the national healthcare system.
Under these circumstances, there is an increasing need
for using therapeutic options which are not only clinic-
ally effective but also economically efficient, in order to
maximize the value for money attained from the scarce
resources invested in health care. In this context, the
aim of the present study was to evaluate the cost-utility
of ranolazine as add-on therapy to standard-of-care
(SoC) compared to SoC alone in patients with stable an-
gina who did not respond adequately to first line therapy
with b-blockers and/or calcium channel antagonists in
the health care setting of Greece.
Methods
A decision tree model [24] was locally adapted to
evaluate the cost-utility of ranolazine as add-on therapy
to SoC, compared to SoC alone, during a 6-month
period (time horizon) in patients with stable angina,
who did not respond adequately to first line therapy
with b-blockers and/or calcium channel antagonists in
Greece. The analysis was conducted from a third-party
payer perspective (National Organization for Health-
care Services Provision [EOPYY]). Because the time
horizon did not exceed 1 year, no discounting was per-
formed both to cost and health outcomes. The model
led to calculation of incremental cost incurred and in-
cremental quality adjusted life years (QALYs) gained
using ranolazine as add-on treatment for stable angina.
The cost-effectiveness of ranolazine was expressed as
an incremental cost-effectiveness ratio (ICER) relative
to SoC. As this study is an economic evaluation ana-
lysis and does not involve human subjects no ethics ap-
proval issues arise. Input data including human
material or human data were derived from other pub-
lished studies performed with the approval of an appro-
priate ethics committee [22, 23, 25–27].
Model structure
The model used is a decision tree constructed on Micro-
soft Excel (Fig. 1), which has two main cohorts of pa-
tients representing both treatment alternatives. On the
one hand, the ranolazine branch represents the treat-
ment using ranolazine as an add-on therapy for the
symptomatic treatment of angina pectoris. On the other
hand, the “base treatment” branch represents the stand-
ard treatment in the same type of patients. The ranola-
zine branch is divided into two sub-branches, which
shows the possibility of adherence or non-adherence by
the patients to the treatment. Patients who do not
adhere to the treatment with ranolazine are treated
immediately with standard treatment, however for the
purpose of the model and following the principle of
intention to treat, these patients remain in the ranola-
zine branch. Whether or not the patient adheres to
the treatment, four possible scenarios are considered,
related to the frequency of angina that might be ex-
perienced at this stage of the model: minimal, mild,
moderate or severe frequency. The transition prob-
abilities depend on whether the patient has continued
the treatment with ranolazine, whether the treatment
has been stopped by the patient, or whether the pa-
tient belongs to the cohort of patients with standard
treatment. Once the patient is in one of these poten-
tial angina frequency groups, hospitalization may or
may not be required. When hospitalization is re-
quired, then an intervention might be needed or not.
Most frequently required interventions at this stage
are coronary artery bypass graft (CABG), or percutan-
eous coronary intervention (PCI). We did not con-
sider mortality in this model related to stable angina
pectoris, because, it has been shown in different stud-
ies that there are not significant differences in the
mortality of patients under evaluation [23, 28].
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Clinical inputs
The clinical inputs considered in the model were: a) transi-
tion probabilities, including the probability of experiencing
minimum, mild, moderate or severe angina frequency, the
probability of being hospitalized, and the probability of be-
ing subjected to a revascularization procedure, and b) utility
values related to non-hospitalization, hospitalization with-
out revascularization, and hospitalization with revasculari-
zation. The above clinical inputs considered in the present
analysis were obtained from relevant clinical and epidemio-
logical trials [22, 23, 25–27]. It is worth noting that the
same published studies were used in a previous publication
of the model [24].
Transition probabilities
As mentioned above, the transition probabilities consid-
ered in the present model are presented in detail else-
where [24]. In brief, the probability of adherence to
ranolazine treatment was estimated at 72 % [23] while
the odds of experiencing at least a minimal frequency of
angina (out of minimal, mild, moderate or severe) epi-
sode was estimated according to the treatment received
[22] (Table 1). At this point it should be noticed that the
frequency of angina classification depended on the self-
administered questionnaire answers. The questionnaire
used was the Seattle angina questionnaire [29]. It led
to grouping of patients onto different categories ac-
cording to their responses. To be more precise, pa-
tients with <0.5 episodes/week, 0.5-3 episodes/week,
3–5.5 episodes/week and > =5.5 episodes/week were
classified to experience minimal, mild, moderate and
severe angina, respectively.
Moreover, the 6-month probability of hospitalization
have been estimated at 20, 20, 27 and 30 % for minimal,
mild, moderate or severe angina frequencies respectively,
based on data obtained from Merlin-TIMI 36 clinical
trial [25] (Table 1).
Of note, it has been found that the probability of
hospitalization is independent of the type of treatment
(ranolazine or SoC) but it depends on the severity of an-
gina. When hospitalization is required, an intervention
might be needed (or not) such as CABG or PCI/Stent
[26] (Table 1). All these data were reviewed and vali-
dated by 3 local experts (C.V., J.P., J.K.) in order to in-
crease the credibility and validity of the model inputs.
Utility weights
QALYs were selected as the measure of effectiveness in
present study. Utility weights are a measure of a patient’s
preference of a particular health state and generally
range from 0 (death) to 1 (perfect health). Utility values
were obtained from the literature [27] (Table 1).
Costing methodology
Since the analysis was conducted from the public third-
party-payer perspective (EOPYY), only health care costs
reimbursed by the payer were included in the model.
The total reimbursement cost reflected and encapsulated
all the possible healthcare resource consumption of pa-
tients during the horizon of analysis (6 months). The
average resource utilization for a Greek patient suffering
from stable angina was extracted from 3 the local ex-
perts using a questionnaire developed to serve the pur-
pose of the present study. The questionnaire was
developed to reflect the disease management in Greece,
and the local experts participating in the present study
confirmed its content validity. In this context, the cost
of anti-anginal drug acquisition, hospitalizations, vascu-
lar interventions and monitoring tests including out-
patient visits, laboratory tests and imaging diagnostic
Fig. 1 Model structure
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examinations were considered in the analysis. All costs
reflect the year 2014 (€).
Drug acquisition cost of anti-anginal drugs
Drug acquisition costs of ranolazine and SoC were
calculated using the latest price bulletin issued by the
Ministry of Health (26.11.2014) [30], as well as the cor-
responding reimbursement prices (Positive List for the
reimbursement of medicines, FEK 3376/16.12.14). The
reimbursement prices were reduced by the patient rele-
vant patient co-payment (25 %) and relative rebates as
they suggested by the corresponding legislation (Official
Government Gazzete, FEK 64/16.1.2014). In particular,
the rebate of 9 % given by manufacturers to get into the
positive list was considered in the analysis. For
ranolazine only, an additional rebate of 2 % was consid-
ered as it is alone in its cluster (Official Government
Gazzete, FEK 64/16.1.2014). At this point, it should be
pointed out that the volume-related rebate ranging from
2 to 12 % could have been considered in the analysis.
Due to lack of volume –related data for all drugs, it was
not taken into account in the base case analysis.
Standard care drug costs have been modelled using
the overall proportions of patients using each thera-
peutic class and the mean daily dose for each drug as
obtained from the 3 local experts and the relevant drug
acquisition cost, calculated as mentioned above. For
each therapeutic class, the active substances (INN) con-
sidered in the analysis reflected the most commonly pre-
scribed drug locally, as obtained from the 3 local
Table 1 Clinical inputs considered in the model
Value of the parameter
Ranolazine (%) SoC (%)
Transition probabilities
Adherence to treatment with ranolazine [23] 0.720
Angina frequency [22]
Minimum 0.040 0.000
Mild 0.605 0.071
Moderate 0.208 0.689
Severe 0.137 0.241
Hospitalization [25]
With minimum angina frequency 0.200 0.200
With mild angina frequency 0.200 0.200
With moderate angina frequency 0.270 0.270
With severe angina frequency 0.300 0.300
Revascularization [26]
Revascularization 0.500 0.500
Revascularization with CABG 0.280 0.280
Revascularization with PTCA 0.720 0.720
Utility values [27]
No hospitalization, minimum angina frequency 0.810 0.840
No hospitalization, mild angina frequency 0.750 0.750
No hospitalization, moderate angina frequency 0.600 0.600
No hospitalization, severe angina frequency 0.390 0.390
Hospitalization without revascularization, minimum angina frequency 0.800 0.800
Hospitalization without revascularization, mild angina frequency 0.740 0.740
Hospitalization without revascularization, moderate angina frequency 0.590 0.590
Hospitalization without revascularization, severe angina frequency 0.380 0.380
Revascularization, minimum angina frequency 0.750 0.750
Revascularization, mild angina frequency 0.690 0.690
Revascularization, moderate angina frequency 0.540 0.540
Revascularization, severe angina frequency 0.330 0.330
CABG: coronary artery bypass graft, PCI/STENT: percutaneous transluminal angioplasty & stenting, SoC: standard of care
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experts. Hence, a weighted cost was calculated for each
therapeutic class based on the distribution of patients to
different active substances. Based on those mentioned
above, the total 6-month acquisition cost for SoC was
calculated at 159.01€.
Regarding ranolazine, based on data provided by local
experts it was considered that during the first two
months 80 % of patients received 750 mg (375 mg twice
daily) as a daily dose, while the remaining 20 % received
1000 mg (500 mg twice daily) as a daily dose and from
the third month and onwards 50 % of patients received
750 mg (375 mg twice daily) as a daily dose, while 40 %
of patients received 1000 mg (500 mg twice daily) as a
daily dose and the remaining 10 % received 1500 mg
(750 mg twice daily) per day. The total 2-month and
4-month acquisition cost for ranolazine was calculated
at 89.27€ and 178.75€ respectively (Additional file 1:
Table S1).
Hospitalization costs
To estimate the total 6-month hospitalization cost
(excluding hospitalizations related to vascular interven-
tions), the reimbursement tariff per hospitalization ob-
tained from the Diagnostic Related Groups (DRGs) tariffs’
list issued by the Greek Ministry of Health [31] was multi-
plied by the number of hospitalizations, as provided by
the 3 local experts. The hospitalization cost at a 6-month
period was found to range from €226.67 in patients ex-
periencing minimal angina episodes to €2451 in patients
experiencing severe angina episodes [Table 2].
Regarding the cost of vascular interventions, the propor-
tion of patients with stable chronic angina undergoing re-
vascularization (i.e. PCI or CABG), as extracted from the
literature [26] and validated by the 3 local experts, was
combined with the reimbursed tariff per revascularization
obtained from the relevant DRGs tariffs’ lists issued by the
Greek Ministry of Health [31]. The cost per CABG and
PCI/stent were found to be €5772 and €1798 respectively.
To account for the effect of angina severity to the
hospitalization cost, the model allowed the proportion of
patients requiring hospitalization (with and without
revascularization) and the hospitalization frequency to
depend on angina severity.
Routine monitoring costs
Routine monitoring costs include outpatient visits, labora-
tory tests (e.g. blood and biochemical tests) and diagnostic
tests. The number of visits, laboratory tests and diagnostic
tests (e.g. echo, MRI etc.) required as well as the propor-
tion of patients undergoing each test were retrieved from
the 3 local experts. The corresponding reimbursed unit
costs were obtained from the Government Gazette (FEK
A’262/16-12-2011) and from the official site of EOPYY
respectively.
The 6-month cost for outpatient visits was found to be
extremely low ranging from €7 in patients suffering from
minimal angina episodes to €31.33 in those suffering
from severe angina. With respect to laboratory and diag-
nostic tests, it was found that the 6-month laboratory
test cost varies from €7.93 to €40.29 and the 6-month
diagnostic tests cost from €40.72 to €123.79 [Table 2].
As with hospitalizations, the model allowed the pro-
portion of patients undergoing to laboratory and diag-
nostic tests, as well as the number of tests and visits to
depend on angina severity.
Data analysis
The aforementioned data were used to get mean esti-
mates of QALY, and total direct costs related to each
comparator (ranolazine + SoC vs. SoC alone). The cost-
effectiveness of ranolazine plus SoC over SoC alone was
evaluated by calculating the incremental cost per QALY
gained (ICER). For a treatment to be considered cost-
effective a willingness-to-pay (WTP) threshold of
€34,000 per QALY was used in the current analysis. This
is based on the WHO guidelines stating that a treatment
should be considered cost-effective if the ICER is up to 3
times the GDP per capita of that country and a treat-
ment is considered highly cost effective at less than 1
times the GDP per capita [32]. The GDP per capita in
Greece was estimated at €17,000 taken from the IMF
estimation of GDP per capita using current prices [33].
Table 2 Other medical costs considered in the model
Medical cost for 6-month period
Angina frequency Hospitalization cost (€)a Outpatient visits cost (€)b Cost of laboratory tests (€)c Cost of diagnostic tests (€)c
Minimal 226.67 7 7.93 40.72
Mild 453.33 9.17 9.41 64.55
Moderate 566.67 19.33 21.78 97.02
Severe 2450.83 31.33 40.29 123.79
aOfficial source: Based in local expert’s opinion and DRG such as K36X (€ 340) and K36M (€ 865) , DRG cost were obtained from FEK 9468/27-3-12
bOfficial source: This cost was obtained by combining of the resources (average of number of visits and % of patients), as they provided by the local expert’s
opinion with the corresponding unit costs obtained from government gazette (FEK A’262/16-12-2011)
cOfficial source: The cost assigned was calculated based on resources used such as average of number of tests and % of patients). These resources were obtained
from the local expert’s opinion and these resources were combined with the related unit costs obtained from official site of EOPYY
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The majority of input data used in the current model
are subjected to variation. Therefore, in order to deal
with uncertainty, a probabilistic sensitivity analysis
(PSA) was performed using a second-order Monte Carlo
simulation. In this analysis, a distribution was assigned
around each parameter (i.e. costs, transition probabilities
etc.) and the aforementioned economic and health out-
comes associated with simultaneously selecting random
values from those distributions were generated. Distribu-
tions were selected based on the nature of variables [34].
In particular, a gamma distribution was used to repre-
sent the uncertainty in costs, because costs are con-
strained on the interval zero to positive infinity and are
often highly skewed. Binomial parameters (i.e. the prob-
ability of hospitalization) and utility values are con-
stricted on the interval zero to one and hence they were
varied according to beta distribution. For multinomial
data such as the probability of experiencing a minimal,
mild, moderate or severe angina episode, a Dirichlet dis-
tribution was used. Then, 5000 estimates of costs, LY,
QALYs, and incremental cost per QALYs were obtained
by applying the bootstrapping technique. The mean
values of the bootstrapped estimates represent unbiased
estimations of the parameters under investigation. The
bootstrap percentile method was used to obtain the un-
certainty appropriate intervals for each parameter [35].
A cost-effectiveness acceptability curve (CEAC) was
plotted, showing the proportion of simulations that are
considered cost-effective at different levels of WTP per
QALY gained.
Moreover, a one-way sensitivity analysis (OWSA) was
undertaken to test the robustness of the results, by
varying individual parameters between low and high
values, in order to ascertain the key drivers of cost-
effectiveness. The upper and lower bounds of all pa-
rameters were set at ± 20 % (assumption) of the base
case values. The parameters evaluated in this analysis
were the cost of ranolazine, the cost of SoC, the cost of
hospitalization with no revascularization, the cost of
hospitalization with CABG, the cost of hospitalization
with PCI/Stent, the probability of patients continuing
on ranolazine therapy, the probability of hospitalization
with minimal angina, the probabilities of hospitalization,
and the utility values. Additionally, one scenario was also
considered for the time horizon of the model, assuming
that it was 1 year instead of 6 months used in the base
case analysis.
All statistical calculations performed using Microsoft
Excel 2010.
Results
Deterministic results
The analysis showed that, the total 6-month cost per pa-
tient was €1170 and € 984, for ranolazine plus SoC and
SoC alone. In terms of health outcomes, the analysis re-
vealed that ranolazine was more effective compared to
SoC alone in terms of QALYs. Patients who received
ranolazine plus SoC gained 0.3155 QALYs while patients
who received SoC alone gained 0.2752 QALYs. Under
the base case assumptions, incremental analysis showed
that ranolazine plus SoC resulted in an incremental cost
of €4620 per QALY gained, well below the predeter-
mined WTP threshold of €34,000 per QALY gained
[Table 3].
One-way sensitivity analysis
The OWSA revealed that the results of the model were
more sensitive to the utility for no hospitalization of
mild angina severity as this parameter was found to have
the greatest effect on ICER followed by the probability
of patients continuing on ranolazine therapy and the
utility for no hospitalization of moderate angina severity.
It is worth noting that in all variations in the parameters
which were considered in the sensitivity analysis the
ranolazine remains a cost-effective treatment, since the
ICER per QALY gained remains well below of the
threshold of €34,000 per QALY gained.
Moreover, when the scenario of 1 year time horizon
was considered in the analysis, ranolazine remained a
cost-effective treatment resulting in an ICER equal to
€6579 per QALY gained (data not presented in details)
[Table 4].
Table 3 Deterministic & probabilistic results for ranolazine plus SoC vs SoC alone
Deterministic results Probabilistic results
Costs Ranolazine SoC Incremental Ranolazine SoC Incremental
Mean (95 % CI)
Total Costs (€) 1170 984 186 1170 (1123; 1213) 985 (933; 1036) 184 (154; 216)
Health outcomes
QALYs 0.3155 0.2752 0.0403 0.3157 (0.3093; 0.3221) 0.2754 (0.2672; 0.2836) 0.0402 (0.0345; 0.0456)
Incremental analysis
ICER per QALY (€) 4620 4904 (3526; 5962)
ICER: incremental cost effectiveness ratio, QALY: quality-adjusted life year, SoC: standard of care, CI: confidence interval
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Probabilistic sensitivity analysis
The PSA confirms the deterministic results [Table 3]. In
particular, the analysis showed that ranolazine was more
cost-effective than SoC for all the simulations. The
CEAC showed that the likelihood of ranolazine being
cost-effective at a WTP threshold of 34,000€ was 100 %.
Furthermore, in the alternative conservative WTP
threshold of €17,000 the CEAC showed that the likeli-
hood of ranolazine being cost-effective over SoC alone
was 99.9 % [Fig. 2].
Discussion
In the present study, an economic analysis was under-
taken to compare, from a payer perspective, the ranola-
zine as add-on therapy to SoC relative with SoC alone
during a 6-month period in patients with chronic stable
angina in Greece. Ranolazine as add-on therapy to SoC
was more expensive treatment regimen as it was found
that the total 6-month treatment cost was higher by
€186 compared to SoC alone. In terms of health out-
comes, ranolazine was more effective as it reduces the
severity and frequency of angina episodes in relation
with SoC, resulting in higher QALYs gained. Hence,
ranolazine was found to be a cost-effective treatment al-
ternative, resulting in an ICER equal to €4620 per QALY
gained well below the predetermined WTP threshold of
€34,000 per QALY gained. Furthermore, the OWSA
Table 4 Results of one-way sensitivity analysis
Input parameter Base case value aLow value ICER aHigh value ICER
Cost of ranolazine €268 €214 €3511 €322 €5725
Cost of SoC €159 €127 €4598 €191 €4643
Cost of hospitalization with no revas (mid, minimal, moderate) €340 €272 €4692 €408 €4549
Cost of hospitalization with no revas (severe) €865 €692 €4438 €1038 €4803
Cost of hospitalization with CABG €5772 €4617 €4841 €6926 €4611
Cost of hospitalization with PCI/Stent €1797 €1438 €4712 €2157 €4528
Probability of patients continuing on Ranolazine therapy 0.72 0.576 €7539 0.864 €2675
Probability of hospitalization with minimal angina 0.20 0.16 €4570 0.24 €4671
Probability of hospitalization with mild angina 0.20 0.16 €3858 0.24 €5393
Probability of hospitalization with moderate angina 0.27 0.21 €5572 0.31 €3684
Probability of hospitalization with severe angina 0.30 0.24 €5497 0.36 €3747
Utility for no hospitalization (minimal angina) 0.81 0.65 €4842 0.97 €4418
Utility for no hospitalization (mild angina) 0.75 0.60 €10,076 0.90 €2938
Utility for no hospitalization (moderate angina) 0.60 0.48 €3369 0.72 €7349
Utility for no hospitalization (severe angina) 0.39 0.31 €4391 0.47 €4875
Utility for hospitalization without revas (minimal angina) 0.80 0.64 €4647 0.96 €4594
Utility for hospitalization without revas (mild angina) 0.74 0.59 €4976 0.89 €4312
Utility for hospitalization without revas (moderate angina) 0.59 0.47 €4335 0.71 €4946
Utility for hospitalization without revas (severe angina) 0.38 0.30 €4572 0.46 €4670
Utility for hospitalization with revas (minimal angina ) 0.75 0.60 €4645 0.90 €4596
Utility for hospitalization with revas (mild angina) 0.69 0.55 €4955 0.83 €4328
Utility for hospitalization with revas (moderate angina) 0.54 0.43 €4353 0.65 €4922
Utility for hospitalization with revas (severe angina) 0.33 0.26 €4576 0.40 €4666
SoC: standard of care, CABG: coronary artery bypass graft, PCI/STENT: percutaneous transluminal angioplasty& stenting, Revas: revascularization
aLow and high values currently based on ± 20 % variation from the base case
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Fig. 2 Cost-effectiveness acceptability curve ranolazine plus SoC vs
SoC alone
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revealed that ranolazine as add-on therapy to SoC
remains a well cost- effective treatment across all
scenarios.
Our findings are in the line with those presented in the
previously conducted economic analyses comparing rano-
lazine as an add-on therapy with SoC alone [24, 36, 37].
More specifically, a cost-utility study conducted in Spain
[24] showed that ranolazine is a highly efficient add-on
therapy for the symptomatic treatment of chronic angina
pectoris with an ICER of €8455 per QALY. Moreover, a
study which was conducted in the USA [36] showed that
ranolazine as add-on to SoC is a cost-effective treatment
in patients with weekly or daily angina with an ICER of
$32,682 per QALY. Similar findings were obtained in a
study conducted in Russia [37], which showed that the use
of ranolazine in patients with > 3 attacks of angina pectoris
per week was clinically and economically substantiated.
Additionally, a retrospective study which performed in
USA [38] showed that adding ranolazine to the treatment
regimen of patients was associated with lower rates of re-
vascularization and lower total costs of care than SoC
(ranolazine:$13,961 vs nitrates :$18,166 and beta blockers/
calcium channel blockers :$17,612).
The methodology adopted was based upon standard
recommendations to conduct economic evaluation and
extensive sensitivity and probabilistic analyses were
conducted to fully explore uncertainty. However, po-
tential limitations to this study should be considered.
Firstly, in the present analysis it was assumed that the
clinical data obtained from the published studies were
applicable to the Greek health care setting. The use of
this data may be questionable, however given the lack
of local related data, this choice was the only source of
relevant clinical data; one may argue that pivotal trials
are almost universally used to build models for pricing
and reimbursement decisions. Secondly, in the absence
of local data, three local experts (cardiologists) with
extensive clinical experience on the management of
chronic stable angina were used to obtain local re-
source utilization and validate some of the assumptions
considered in the model. This may raise concerns about
the subjectivity of model inputs and leave space for
challenging the study results. Nevertheless a series of
sensitivity analyses indicated that our model and
outcomes are valid, since the main results remained
unchanged. Furthermore, the current analysis was
conducted from the third party payer perspective and
as such only direct costs were considered. However a
more complete analysis from a broader (societal) per-
spective may also be worthwhile. True health care and
patient direct and indirect costs are higher than those
considered in the present analysis, and therefore the
cost-utility of a new therapy may be more favorable
from a societal perspective.
Finally, it should be noted that the results have to be
considered in the strict Greek setting and on the basis of
the present time resource and drug prices. If any of the
underlying parameters change, so may the results and
the conclusions of the analysis.
Conclusions
The present study suggests that ranolazine as add-on
treatment provides greater health benefits and is more
costly. However, the additional cost per QALY gained is
well below the predetermined WTP threshold of
€34,000 per QALY gained. Therefore, the present study
indicates that ranolazine as add-on treatment can be
considered a cost-effective alternative for the symptom-
atic treatment of patients with chronic stable angina in
Greece.
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